Injectable β-TCP/MCPM cement associated with mesoporous silica for bone regeneration: characterization and toxicity...

Bone graft substitutes are essential in regenerative medicine to support tissue healing. Calcium phosphate cement is a promising candidate due to its self-setting properties and biocompatibility. Mesoporous materials are also gaining attention for their ability to carry biological molecules. However, the combination of these materials for bone regeneration remains underexplored. Current research lacks data on the long-term effects of mesoporous silica in composite cements. This gap motivated the investigation of a new injectable cement formulation. The study aimed to assess both physicochemical and biological properties. Understanding these properties is crucial for clinical applications. This research contributes to the development of advanced bone graft materials.

This research aimed to evaluate a novel injectable cement for bone regeneration. The cement combined β-TCP-MCPM with mesoporous silica particles. The goal was to assess its mechanical and biological performance. The study focused on injectability, porosity, and bioactivity. It also examined the material’s degradation in simulated body fluid. Toxicity was tested using CHO-K1 cell culture. The researchers wanted to determine if the material could support bone repair. This study provides insights into the potential of composite cements for clinical use.

The researchers synthesized β-TCP-MCPM cement with mesoporous silica particles. They tested the material’s mechanical strength and microstructure. Porosity was measured to assess its suitability for bone growth. Injectability was evaluated to determine ease of application. Bioactivity was studied by soaking the cement in simulated body fluid. Toxicity was assessed using CHO-K1 cells and cell viability tests. DNA damage was measured to evaluate long-term safety. The study combined material science and cell biology techniques.

The β-TCP-MCPM cement showed improved bioactivity after soaking in simulated body fluid. Mesoporous silica enhanced the material’s physicochemical properties. Mechanical strength and porosity were within acceptable ranges for bone grafts. The cement was injectable, making it suitable for minimally invasive procedures. Higher concentrations of cement extracts reduced cell viability in CHO-K1 cultures. However, reproductive capacity remained unaffected at those concentrations. DNA damage was not significant, suggesting limited genotoxic risk. The material demonstrated potential for bone regeneration applications.

The β-TCP-MCPM cement with mesoporous silica may serve as a bone substitute. The material showed good mechanical and bioactive properties. Mesoporous silica improved the cement’s performance compared to silica-free versions. Toxicity was low at lower concentrations, though higher doses reduced cell viability. The material did not compromise cell reproduction or DNA integrity. These findings suggest the cement is safe for bone repair applications. Further studies are needed to confirm long-term clinical safety. The results support continued research into composite bone graft materials.